EDMONTON, March 27 /CNW/ - Isotechnika Inc. announced today that the
International Nonproprietary Name (INN) expert committee has accepted the
proposed generic name of its lead immunosuppressive drug, ISA247.
ISA247 will now be referred to as voclosporin. The name will serve to
identify the active pharmaceutical substance during the drugs' life-time
Voclosporin is a next generation calcineurin inhibitor, which recently
completed a Phase 2b North American trial for the prevention of kidney
rejection following transplantation. An extension to the Phase 2b trial and a
combined Phase 3 European/Canadian trial for the treatment of moderate to
severe psoriasis are ongoing. Our partner, Lux Biosciences, is currently
conducting three separate Phase 2/3 pivotal trials investigating voclosporin
(referred to as LX211 by Lux) for the treatment of uveitis.
"This completes the process, in combination with the earlier USAN
approval, of obtaining a generic name for our lead immunosuppressive drug,"
said Dr. Robert Foster, Isotechnika's Chairman & CEO.
Edmonton-based Isotechnika Inc. is an international biopharmaceutical
company focused on the discovery and development of novel immunosuppressive
therapeutics that are designed to offer advantages over other currently
available treatments. There is a significant unmet medical need in the
treatment of both solid organ transplantation and autoimmune disease. It is
estimated that the market potential exceeds $2 billion annually in sales for
calcineurin inhibitors such as voclosporin.
Isotechnika Inc. is a publicly traded company on the Toronto Stock
Exchange under the symbol "ISA". More information on Isotechnika can be found
Partnerships with Isotechnika Inc.
- Roche retains an option to continue development of the transplant
indications based on the successful completion of the ongoing
Phase 2b kidney transplant trial.
- Atrium Medical Corporation has exclusive worldwide licensing
agreement for use of voclosporin and TAFA93 with drug eluting devices
for non-systemic treatment of vascular, cardiovascular, target vessel
and tissue disorders.
- Lux Biosciences Inc. was granted worldwide rights to develop and
commercialize voclosporin for the treatment and prophylaxis of all
This press release may contain forward-looking statements. Forward
looking statements, including the Company's belief as to the potential of its
products, the Company's expectations regarding the issuance of additional
patents and the Company's ability to protect its intellectual property,
involve known and unknown risks and uncertainties, which could cause the
Company's actual results to differ materially from those in the forward
looking statements. Such risks and uncertainties include, among others, the
availability of funds and resources to pursue research and development
projects, the ability to economically manufacture its products, the potential
of its products, the success and timely completion of clinical studies and
trials, the Company's ability to successfully commercialize its products, the
ability of the Company to defend its patents from infringement by third
parties, and the risk that the Company's patents may be subsequently shown to
be invalid or infringe the patents of others. Investors should consult the
Company's quarterly and annual filings with the Canadian commissions for
additional information on risks and uncertainties relating to the
forward-looking statements. Investors are cautioned against placing undue
reliance on forward-looking statements.
For further information:
For further information: Dr. Robert Foster, Chairman & CEO, Isotechnika
Inc., (780) 487-1600 (246), (780) 484-4105 (fax), email@example.com;
Stephanie Gillis-Paulgaard, Director, Corporate Communications, Isotechnika
Inc., (780) 909-4661, (780) 487-4105 (fax), firstname.lastname@example.org